黑线科技

最新新闻

• 评级变动
  Analysts Offer Insights on Technology Companies: Klaviyo, Inc. Class A (KVYO), BlackLine (BL) and Infineon Technologies AG (OtherIFNNF)
  TipRanks · 2026/5/6
• 评级变动
  William Blair Initiates BlackLine(BL.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/6/4
• 评级变动
  BofA Securities Maintains BlackLine(BL.US) With Sell Rating, Maintains Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/7/23
• 评级变动
  D.A. Davidson Maintains BlackLine(BL.US) With Hold Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/10
• 公司公告
  Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. Voluntarily Discloses an Announcement Regarding the Inclusion of BL-M05D1 for Injection in the Breakthrough Therapy Designation List for Patients with CLDN18.2‑Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Who Have Previously Received First-Line Standard Therapy.
  SZSI · 2026/9/28
• A Quick Look at Today's Ratings for BlackLine(BL.US), With a Forecast Between $35 to $36
  \u5e02\u573a\u8d44\u8baf · 2026/8/5
• 公司公告
  Bailitianheng: Sichuan Bailitianheng Pharmaceutical Co., Ltd. voluntarily discloses an announcement regarding the triggering of milestone payment conditions under the global strategic cooperation agreement between its wholly owned subsidiary, SystImmune, and Bristol-Myers Squibb, concerning Yizekang? (LunKang Yilong Tuodan Kang, BL-B01D1/iza-bren).
  SZSI · 2026/9/22
• 评级变动
  BofA Securities Initiates BlackLine(BL.US) With Sell Rating, Announces Target Price $26
  \u5e02\u573a\u8d44\u8baf · 2026/5/12
• D.A. Davidson Downgrades BlackLine(BL.US) to Sell Rating, Announces Target Price $23
  \u5e02\u573a\u8d44\u8baf · 2026/9/28
• 公司公告
  Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. Voluntarily Discloses an Announcement Regarding the Completion of Dosing in the First Subject of the Global Multicenter Phase III Clinical Trial Evaluating BL-M14D1 for Injection (DLL3 ADC) in Combination with Immunotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer.
  SZSI · 2026/8/7
• 公司公告
  Baili Tianheng: Announcement by Sichuan Baili Tianheng Pharmaceutical Co., Ltd. on the Voluntary Disclosure of the Approval Notice for Clinical Trials of BL-M12D1 Injection (ADC) for the Treatment of Hematologic Malignancies
  SZSI · 2026/9/28
• A Quick Look at Today's Ratings for BlackLine(BL.US), With a Forecast Between $26 to $45
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• Citi Maintains BlackLine(BL.US) With Buy Rating, Cuts Target Price to $45
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• Baili Tianheng (688506.SH): BL-M05D1 for Injection (Claudin18.2 ADC) for patients with CLDN18.2-positive advanced gastric cancer or gastroesophageal junction adenocarcinoma who have previously received first-line standard therapy has been included in the list of breakthrough therapy designations.
  Gelonghui Finance · 2026/9/27
• 公司公告
  Baili Tianheng: Sichuan Baili Tianheng Pharmaceutical Co., Ltd. voluntarily discloses an announcement regarding the completion of enrollment of the first subject in a Phase III clinical trial evaluating lunkangyilongtuodanmab/iza-bren (BL-B01D1/iza-bren) for the treatment of advanced HR-positive, HER2-negative breast cancer patients who have previously received endocrine therapy and experienced di
  SZSI · 2026/7/24
• 评级变动
  A Quick Look at Today's Ratings for BlackLine(BL.US), With a Forecast Between $35 to $53
  \u5e02\u573a\u8d44\u8baf · 2026/5/7
• 评级变动
  Morgan Stanley Downgrades BlackLine(BL.US) to Hold Rating, Cuts Target Price to $33
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Citi Maintains BlackLine(BL.US) With Buy Rating, Maintains Target Price $53
  \u5e02\u573a\u8d44\u8baf · 2026/6/25
• 评级变动
  Citi Maintains BlackLine(BL.US) With Buy Rating, Cuts Target Price to $53
  \u5e02\u573a\u8d44\u8baf · 2026/5/8
• 评级变动
  A Quick Look at Today's Ratings for BlackLine(BL.US), With a Forecast Between $37 to $50
  \u5e02\u573a\u8d44\u8baf · 2026/5/6

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。